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September 2011924 AbstractsIs Vascular Surgery Giving up the Vascular Laboratory?
Anil Hingorani, Enrico Ascher, Natalie Marks, Alexsander Shiferson, DO,
Daniel Jung, DO, Robert Jimenez, MD, Theresa Jacob, PhD, Maimonon-
ides Medical Center, Brooklyn, NY
Objective(s): In an attempt to identify the concerns of vascular fellows
regarding their training in vascular surgery, we conducted an anonymous
survey consisting of 22 questions at an annual national meeting held yearly
in March from 2004 to 2010.
Methods: The fellows were asked to assess their endovascular, open,
and vascular laboratory experience as excellent, satisfactory, or mixed. They
were queried about who trained them in their endovascular skills, the quality
of their didactics, and amount of small cases that yielded no learning
experience. Of the 466 attendees, 376 (80%) completed the survey. Up to
84% of those surveyed were men. Second-year fellows comprised up to 66%
of those surveyed.
Results: Most (79%) were satisfied with their endovascular experience
during their fellowship, and 81% were satisfied with their experience with
open cases. Interventional skills were obtained from a vascular surgeon
(84%), an interventional radiologist (9%), a cardiologist (1%), or a mixture
(5%). The didactics were felt to be excellent, satisfactory, or required some or
much improvement in 20%, 64%, 11%, and 4% respectively. The distribution
of nonlearning cases was felt to be excellent, satisfactory, or required some or
much improvement in 42%, 45%, 10%, and 3% respectively. However, only
64% thought their vascular laboratory experience was excellent or satisfac-
tory. Only 36% actually performed the vascular duplex examination, and
only 47% felt that they would feel comfortable in managing a vascular
laboratory. Forty-six percent suggested that finding the type of job they
wanted was easy in 46% or moderately difficult in 46%. Most (72%) felt that
future demand for manpower in vascular surgery will exceed available
manpower. In the 2004 survey, the primary source of training for interven-
tional skill was a vascular surgeon in 77% and this increased to 100% in 2010.
No other major significant differences were noted from year to year.
Conclusions: The results of this survey suggest that several significant
issues are reflected in the minds of vascular trainees. These data suggest that
vascular fellows are not being adequately trained in the vascular laboratory.
Because the trainees represent the future of our field, we suggest that the
vascular laboratory become a specific area of focus in the fellowship training.
Do Ethnic Differences and TransAtlantic InterSociety Consensus Dis-
tribution Affect the Incidence of Lower Extremity Amputation?
Nicholas J. Gargiulo, III, David O’Connor, MD, Yana Etkin, Ashish Raju,
Larry Scher, William Suggs, Evan Lipsitz, Albert Einstein College of Med-
icine, Bronx, NY
Objective(s): There has been recent interest in ethnic differences with
a wide variety of disease entities. Some evidence has suggested that particular
ethnic populations may be more susceptible to severe manifestations of
peripheral arterial disease. This study was initiated to better determine what
if any factors affected a diverse ethnic population afflicted with critical limb
ischemia (CLI).
Methods: We reviewed all patients presenting with CLI from January
1, 2007, to December 31, 2007. CLI was defined as ischemic rest pain,
nonhealing ulceration, or gangrene (Rutherford class 4 and 5) for which a
major amputation was imminently required. All patients underwent conven-
tional arteriography and if possible, an endovascular, open, or hybrid pro-
cedure for successful limb salvage. Multivariate logistic regression was used
to determine any association between ethnic background and Rutherford
class, comorbid conditions, TransAtlantic InterSociety Consensus II (TASC
II) classification, runoff score, types of intervention (open, endovascular, or
hybrid), prior and repeat procedures, death, and 1-year amputation-free
survival (outcome).
Results: During this 1-year period, 148 patients presented with pri-
mary, secondary, or tertiary CLI. Of these, 58 patients (40%) were black, 57
(40%) were Latino, 28 (20%) were white, and ethnic background could not
be determined in 5. There was no difference in clinical presentation among
the three races. All groups had similar rates of TASC II D iliac disease;
however, black patients had a higher prevalence of TASC II D femoropop-
liteal disease. Latino and white patients had a higher prevalence of TASC II
D infrapopliteal disease. Primary patency rates among the ethnic groups
remained similar at 1 year, however the Latino group displayed poorer
patency after 1 year compared the black and white groups. All three ethnic
groups had a similar 1-year amputation rate of 6.4%.
Conclusions: There does not appear to be a significant difference
among racial groups in clinical presentation. There are disparate lesion
distributions among the three ethnic groups, with more severe TASC II D
infrapopliteal disease in the Latino group, possibly affecting primary pa-
tency. There was no clear ethnic difference amongst the groups with regards
to overall amputation rate.
m
sole of Prostaglandins in Venous Thrombus Resolution in a Murine
odel of Thrombosis
uzanne A. Siefert, MD, Khahn Nguyen, MD, Rajabrata Sarkar, MD, PhD,
niversity of Maryland, Baltimore, Md
Objective(s): Thrombus resolution is a critical process after deep
enous thrombosis and the molecular mechanisms involved remain largely
ndefined. Prior studies in our laboratory indicate that selective cyclooxy-
enase 2 (COX-2) inhibitors, which have increased cardiovascular compli-
ations, impair thrombus resolution. COX-2 is involved in the generation of
everal prostaglandin products. The purpose of this study was to define the
ffects of several individual prostaglandins on thrombus resolution to better
nderstand the basic mechanisms of thrombus resolution as well as the
ffects of COX-2 inhibitors in vascular biology.
Methods: CD-1 outbred mice underwent caval ligation and adminis-
ration of a variety of prostanoids via Alzet minipumps, then were harvested
t day 4 or 12 and measured for thrombus weight. Six groups were used: (1)
ormal saline vehicle with trace methyl acetate (used as controls for groups
-5), (2) phosphate buffer vehicle with sodium hydroxide, pH 10 (used as
ontrol for group 6), (3) thromboxane (0.1 mg/kg/day), (4) misoprostol
prostaglandin E analog; .1 mg/kg/day), (5) iloprost (prostaglandin E
PGE] and prostaglandin I [PGI] analog; 0.1 mg/kg/day), and (6) PGI2
0.1 mg/kg/day).
Results: Thromboxane decreased thrombus resolution, as assessed by
hrombus weight on postoperative day 12 (control, 0.221  0.064 mg/g
n 10]; thromboxane, 0.359 0.172 mg/g [n 9]; P .03). However,
o difference was seen in thrombus resolution with the administration of
isoprostol (control, 0.221 0.064 mg/g [n 10]; misoprostol, 0.249
.061 mg/g [n  7]; P  .368), iloprost (control, 0.221  .064 mg/g [n
10]; iloprost, 0.176  0.088 mg/g [n  9]; P  .22), or PGI (control,
.286 0.05mg/g [n 8]; PGI, 0.254 0.092mg/g [n 9]; P .396).
o further investigate if thromboxane had an effect of thrombus formation,
e compared thrombus weights at day 4 and found no difference (control,
.84 0.181 mg/g [n 7]; thromboxane, 0.822 0.199 mg/g [n 8];
 .85).
Conclusions: The administration of thromboxane, but not PGE, PGI,
r their combination, had a significant effect on thrombus resolution. This
ffect of thromboxane could account for the difference seen previously
etween nonsteroidal anti-inflammatory drugs and COX-2 inhibitors, be-
ause the latter lacks inhibition of thromboxane. This study also identifies
hromboxane as a novel potential inhibitory target to accelerate thrombus
esolution.
yslipidemia Regulates Thrombospondin-1–Induced Vascular Smooth
uscle Cell Chemotaxis
ristopher G. Maier, PhD, Sufyan A. Siddiqui, Munyaradzi Chimukangara
homas Snyder, Keri A. Seymour, DO, Yumna Saeed, Jeffrey J. Stein, MD,
ivian Gahtan, MD, SUNY Upstate Medical University, Syracuse, NY
Objective(s): Nearly one-third of Americans have dyslipidemia, as
ssessed by decreased high-density lipoprotein (HDL) and increased low-
ensity lipoprotein (LDL) levels. Dyslipidemia and increased oxidized LDL
oxLDL) levels are risk factors for atherosclerosis and restenosis due to
ntimal hyperplasia (IH) after balloon angioplasty. A key process in IH
evelopment is vascular smooth muscle (VSMC) cell migration. LDL and
xLDL stimulate VSMC migration and potentiate agonist-induced migra-
ion. In contrast, HDL inhibits VSMCmigration to pro-migratory agonists.
DLmay induce migration through its lysophosphatidic acid (LPA)moiety,
ndHDLmay inhibit migration through its sphingosine-1-phosphate (S1P)
oiety, which stimulates cyclooxygenase 2 (COX2)-dependent prostacyclin
elease. The effect of LDL, oxLDL, and HDL on thrombospondin-1
TSP-1)–induced VSMC migration, however, has not been studied. One of
he ways the matricellular glycoprotein, TSP-1, contributes to IH develop-
ent is by inducing VSMC migration. For this study, the interaction of
holesterol components and TSP-1 on VSMC migration was determined.
e hypothesized that HDL, S1P and would prostacyclin inhibit, and LDL,
xLDL, and LPA would augment TSP-1–induced VSMC chemotaxis.
Methods:Migration was assessed using a modified Boyden chemotaxis
hamber. Quiescent VSMCs were pretreated for 20 hours with serum-free
edia (SFM), HDL (75 g/mL), LDL (150 g/mL), or oxLDL (10
g/mL). Chemotaxis to SFMor TSP-1 (20g/mL)was determined. Next,
he effect of S1P (1M), LPA (1M), and iloprost (a stable prostacyclin
nalog, 100nM) pretreatment for 20 minutes on TSP-1–induced che-
otaxis was determined. Assays were performed in triplicate and analyzed by
nalysis of variance, with P  .05 as significant.
Results: TSP-1–induced VSMC chemotaxis was inhibited by HDL
–42%), whereas LDL (72%) and oxLDL (61%) augmented TSP-1–induced
SMC chemotaxis. S1P (–52%) and iloprost (–62%) inhibited, and LPA
39%) augmented, TSP-1–induced VSMC chemotaxis.
Conclusions: Cholesterol regulates TSP-1–induced VSMC che-
otaxis. HDL inhibition of chemotaxis is likely due to S1P and its ability to
timulate COX-2–dependent prostacyclin release. LDL and oxLDL in-
